Xanomeline quercetin complexes and trospium salts

WO2025255488A9PCT designated stage Publication Date: 2026-05-28KARUNA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
KARUNA THERAPEUTICS INC
Filing Date
2025-06-06
Publication Date
2026-05-28

AI Technical Summary

Technical Problem

Existing forms of xanomeline and trospium compounds lack control over solubility, bioavailability, ease of synthesis, and physical stability, which are crucial for effective pharmaceutical formulations.

Method used

Development of xanomeline-quercetin complexes and trospium pamoate salts in various crystalline forms, such as Forms I, IA, II, III, IV, V, and VI, which exhibit lower solubility, increased thermal stability, and suitable particle size, particularly Form C of trospium pamoate showing significantly lower water solubility and stability.

Benefits of technology

The crystalline forms provide favorable properties for long-acting or long-release pharmaceutical formulations, enhancing solubility control and stability, suitable for treating CNS diseases like schizophrenia and Alzheimer's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025032683_28052026_PF_FP_ABST
    Figure US2025032683_28052026_PF_FP_ABST
Patent Text Reader

Abstract

Complexes (e.g., co-crystals) of xanomeline-quercetin, which may be in specific crystalline form, and trospium pamoate salt, which may be in specific crystalline form, as well as pharmaceutical compositions comprising such and methods for their uses, singly or in combination.
Need to check novelty before this filing date? Find Prior Art